Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan in metastatic triple-negative breast cancer
NCT04454437Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in triple-negative breast cancer (TNBC), sponsored by Gilead Sciences. Started Oct 2020; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04454437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04454437.